TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

NCT04988945 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

PROCEDURE: TACE
RADIATION: SBRT
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

The University of Hong Kong